| Test cohort (n = 14) | Validation cohort (n = 26) | Total group (n = 40) |
---|---|---|---|
Demographics | Â | Â | Â |
Age, years | 55 ± 10 | 59 ± 11 | 58 ± 11 |
Female, % | 86 | 85 | 85 |
Disease characteristics | Â | Â | Â |
RA duration, years | 11 (5 to 21) | 6 (2 to 16) | 8 (3 to 17) |
DAS28-score | 5.7 ± 1.0 | 5.8 ± 1.2 | 5.8 ± 1.2 |
ESR, mm/hr | 14 (9 to 31) | 29 (13 to 50) | 23 (12 to 42) |
CRP, mg/L | 9 (3 to 19) | 14 (6 to 27) | 12 (4 to 25) |
IgM RF positive, % | 71 | 63 | 68 |
ACPA positive, % | 79 | 70 | 73 |
Erosive diseases, % | 93 | 59 | 72 |
Medication | Â | Â | Â |
Previous biologicals, n | 2 (1 - 2) | 2 (1 - 2) | 2 (1 - 2) |
> 1 Biological in history, % | 50 | 50 | 50 |
Previous DMARDS, n | 4 (4 - 5) | 3 (3 - 4) | 4 (3 - 4) |
Current prednisolone use, % | 93 | 63 | 70 |
Prednisolone dosage, mg/day | 9 (7 - 13) | 5 (0 - 10) | 8 (0 - 10) |
Current DMARD use, % | 93 | 77 | 83 |
Current statin use, % | 21 | 13 | 18 |
Response | Â | Â | Â |
ΔDAS28 | -1.6 (-2.7 - -0.5) | -1.0 (-1.5 - 0.2) | -1.0 (-2.0 - 0.3) |
ΔDAS28 > 1.2, % EULAR responders, % | 57 64 | 65 50 | 63 55 |